TRIMETHOBENZAMIDE HYDROCHLORIDE

Post-LOE

trimethobenzamide hydrochloride

PharmaIN

ANDAORALCAPSULE

Approved

Aug 2003

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

TRIMETHOBENZAMIDE HYDROCHLORIDE (trimethobenzamide hydrochloride) by PharmaIN is 12. Approved for vomiting, for nausea associated with gastroenteritis. First approved in 2003.

Drug data last refreshed 1w ago

Mechanism of Action

12.1 Mechanism of Action The mechanism of action of trimethobenzamide as determined in animals is obscure, but may involve the chemoreceptor trigger zone (CTZ), an area in the medulla oblongata through which emetic impulses are conveyed to the vomiting center; direct impulses to the vomiting center…

Worked on TRIMETHOBENZAMIDE HYDROCHLORIDE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

TRIMETHOBENZAMIDE HYDROCHLORIDE

Mechanism of Action

Indications (2)

Clinical Trials (1)